Sancho, Juan-ManuelMarin-Niebla, AnaFernandez, SilviaCapote, Francisco-JavierCañigral, CarolinaGrande, CarlosDonato, EvaZeberio, IzaskunPuerta, Jose-ManuelRivas, AlfredoPerez-Ceballos, ElenaVale, AnaMartin Garcia-Sancho, AlejandroSalar, AntonioGonzalez-Barca, EvaTeruel, AnabelPastoriza, CarmenConde-Royo, DiegoSanchez-Garcia, JoaquinBarrenetxea, CristinaArranz, ReyesHernandez-Rivas, Jose-AngelRamirez, Maria-JoseJimenez, AroaRubio-Azpeitia, Eva2023-05-032023-05-032022-04-19Sancho JM, Marín-Niebla A, Fernández S, Capote FJ, Cañigral C, Grande C, et al. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. Int J Hematol. 2022 Sep;116(3):381-392http://hdl.handle.net/10668/21263This retrospective study evaluated 66 patients diagnosed with relapsed and/or refractory mantle cell lymphoma (R/R MCL) treated with ibrutinib in Spain in routine clinical practice. At diagnosis, patients had a median age of 64.5 years, 63.6% presented with intermediate/high sMIPI (simplified prognostic index for advanced-stage mantle cell lymphoma), 24.5% had the blastoid variant, and 55.6% had a Ki67 > 30%. Patients had received a median of 2 prior lines of therapy (range 1-2; min-max 1-7). Overall response rate was 63.5%, with 38.1% of patients achieving complete response (CR). With a median duration of ibrutinib exposure of 10.7 months (range 5.2-19.6; min-max 0.3-36), the median progression-free survival (PFS) and overall survival (OS) were 20 months [95% confidence interval (CI) 8.8-31.1] and 32 months (95% CI 22.6-41.3), respectively, and were not reached in patients achieving CR. No grade ≥ 3 cardiovascular toxicity or bleeding was reported. This study supports that treatment with ibrutinib leads to high response rates and favorable survival outcomes in patients with R/R MCL.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Clinical practiceIbrutinibMantle-cell lymphomaReal-world evidenceRelapsed/refractoryÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de CádizAdenineAdultHumansLymphoma, mantle-cellMiddle agedNeoplasm recurrence, localPiperidinesPyrazolesPyrimidinesRetrospective studiesresearch article35551632open accessAdeninaEstudios retrospectivosLinfoma de células del mantoPiperidinasPirazolesPirimidinasRecurrencia local de neoplasia10.1007/s12185-022-03367-z1865-3774PMC9392694https://link.springer.com/content/pdf/10.1007/s12185-022-03367-z.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392694/pdf